Your browser doesn't support javascript.
loading
Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.
Angin, Mathieu; Wong, Glenn; Papagno, Laura; Versmisse, Pierre; David, Annie; Bayard, Charles; Charmeteau-De Muylder, Bénédicte; Besseghir, Amel; Thiébaut, Rodolphe; Boufassa, Faroudy; Pancino, Gianfranco; Sauce, Delphine; Lambotte, Olivier; Brun-Vézinet, Françoise; Matheron, Sophie; Rowland-Jones, Sarah L; Cheynier, Rémi; Sáez-Cirión, Asier; Appay, Victor.
Afiliação
  • Angin M; Institut Pasteur, Unité HIV Inflammation et Persistance, Paris 75015, France;
  • Wong G; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses, INSERM U1135, Paris 75005, France; Nuffield Department of Medicine, Headington, Oxford OX3 7FZ, United Kingdom;
  • Papagno L; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses, INSERM U1135, Paris 75005, France;
  • Versmisse P; Institut Pasteur, Unité HIV Inflammation et Persistance, Paris 75015, France;
  • David A; Institut Pasteur, Unité HIV Inflammation et Persistance, Paris 75015, France;
  • Bayard C; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses, INSERM U1135, Paris 75005, France;
  • Charmeteau-De Muylder B; INSERM U1016, Institut Cochin, Cytokines and Viral Infections Team, Paris 75014, France; CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France;
  • Besseghir A; Centre de Méthodologie et de Gestion des Essais Cliniques de l'INSERM U1219, Virus de l'Immunodéficience Humaine, Hépatites Virales et Comorbidités, Épidémiologie Clinique et Santé Publique, Bordeaux 33076, France;
  • Thiébaut R; Centre de Méthodologie et de Gestion des Essais Cliniques de l'INSERM U1219, Virus de l'Immunodéficience Humaine, Hépatites Virales et Comorbidités, Épidémiologie Clinique et Santé Publique, Bordeaux 33076, France;
  • Boufassa F; INSERM U1018, Centre de Recherche en Epidémiologie et Santé des Populations, Université Paris Sud, Le Kremlin Bicêtre 94270, France;
  • Pancino G; Institut Pasteur, Unité HIV Inflammation et Persistance, Paris 75015, France;
  • Sauce D; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses, INSERM U1135, Paris 75005, France;
  • Lambotte O; INSERM UMR 1184, Immunologie des Maladies Virales et Autoimmunes, Le Kremlin Bicêtre 94270, France; Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne, Hôpitaux Universitaires, Le Kremlin Bicêtre 94270, France; Université Paris Sud, Le Kremlin Bicêtre 94270, France;
  • Brun-Vézinet F; Assistance Publique-Hôpitaux de Paris, Laboratoire de Virologie, Hôpital Bichat, Paris 75018, France;
  • Matheron S; INSERM UMR 1137, Infections, Antimicrobiens, Modélisation, Evolution, Université Paris Diderot, Sorbonne Paris Cité, Paris 75018, France; and Assistance Publique-Hôpitaux de Paris, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat, Paris 75018, France.
  • Rowland-Jones SL; Nuffield Department of Medicine, Headington, Oxford OX3 7FZ, United Kingdom;
  • Cheynier R; INSERM U1016, Institut Cochin, Cytokines and Viral Infections Team, Paris 75014, France; CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France;
  • Sáez-Cirión A; Institut Pasteur, Unité HIV Inflammation et Persistance, Paris 75015, France; victor.appay@upmc.fr asier.saez-cirion@pasteur.fr.
  • Appay V; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses, INSERM U1135, Paris 75005, France; victor.appay@upmc.fr asier.saez-cirion@pasteur.fr.
J Immunol ; 197(7): 2787-95, 2016 10 01.
Article em En | MEDLINE | ID: mdl-27566819
ABSTRACT
Compared with HIV-1, HIV-2 infection is characterized by a larger proportion of slow or nonprogressors. A better understanding of HIV-2 pathogenesis should open new therapeutic avenues to establish control of HIV-1 replication in infected patients. In this study, we studied the production of CD8(+) T cells and their capacity for viral control in HIV-2 controllers from the French ANRS CO5 HIV-2 cohort. HIV-2 controllers display a robust capacity to support long-term renewal of the CD8(+) T cell compartment by preserving immune resources, including hematopoietic progenitors and thymic activity, which could contribute to the long-term maintenance of the CD8(+) T cell response and the avoidance of premature immune aging. Our data support the presence of HIV-2 Gag-specific CD8(+) T cells that display an early memory differentiation phenotype and robust effector potential in HIV-2 controllers. Accordingly, to our knowledge, we show for the first time that HIV-2 controllers possess CD8(+) T cells that show an unusually strong capacity to suppress HIV-2 infection in autologous CD4(+) T cells ex vivo, an ability that likely depends on the preservation of host immune resources. This effective and durable antiviral response probably participates in a virtuous circle, during which controlled viral replication permits the preservation of potent immune functions, thus preventing HIV-2 disease progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-2 / Linfócitos T CD8-Positivos / Linfopoese Tipo de estudo: Diagnostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-2 / Linfócitos T CD8-Positivos / Linfopoese Tipo de estudo: Diagnostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article